Mark Watling

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation

Sophie Glatt, Dominique Baeten, Terry Baker et al. · Annals of the Rheumatic Diseases · 2017 · 259 citations · Full text

Medicine, Immunology, Pharmacology +17

Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 – 800 µg in healthy volunteers

Alexander Fisher, Mark Watling, Alexandra A. Smith et al. · International Journal of Clinical Pharmacology and Therapeutics · 2010 · 64 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188

Alexander Fisher, Mark Watling, Arlene Smith et al. · International Journal of Clinical Pharmacology and Therapeutics · 2010 · 62 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +15

Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story

Bruno P. Imbimbo, Claudia Balducci, Stefania Ippati et al. · Neural Regeneration Research · 2022 · 59 citations · Full text

Life Sciences, Neurobiology, Neuroscience +16

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study

Sophie Glatt, Peter C. Taylor, Iain B. McInnes et al. · Annals of the Rheumatic Diseases · 2019 · 55 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16